{"name":"Neurocrine Biosciences","slug":"neurocrine-biosciences","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":200000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Ongentys","genericName":"BIA 9-1067","slug":"bia-9-1067","revenue":200000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"2020-01-01","label":"Ongentys first approved","drug":"Ongentys","drugSlug":"bia-9-1067","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":200000000,"percentOfTotal":100,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Ongentys","genericName":"BIA 9-1067","slug":"bia-9-1067","indication":"Parkinson's disease","status":"marketed","revenue":200000000}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"NBI-1117570","genericName":"NBI-1117570","slug":"nbi-1117570","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Ongentys","genericName":"BIA 9-1067","slug":"bia-9-1067","phase":"marketed","mechanism":"Ongentys works by blocking the enzyme that breaks down dopamine, allowing more dopamine to be available in the brain.","indications":["Parkinson's disease"],"catalyst":""},{"name":"NBI-1117570","genericName":"NBI-1117570","slug":"nbi-1117570","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-08","type":"deal","source":"Indian Pharma Post","summary":"Neurocrine Biosciences to acquire Soleno Therapeutics for $2.9 billion - Indian Pharma Post","headline":"Neurocrine Biosciences to acquire Soleno Therapeutics for $2.9 billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQVHM2TTdSWjZEb0JvQkRveFYwc1RyRGxNVEVJSXNvTXRJRmNfc0NSa0YzT0VEN0VRSHpNbWktZ0VpU01kNm9XZHRvRFBMVXpvTW9mZWlTWklodFU4ZG4yODcyY1UybHU5TVNkajF0MjlkdWFuNUJVSy00WlJtR2l6NFllZGRMUkFlWTRoU01HaTBITmdBdXdsWWpWd3hhdFpLRy1OM01lNUs?oc=5","date":"2026-04-07","type":"deal","source":"The Pharma Letter","summary":"Neurocrine expands portfolio with buy of Soleno Therapeutics - The Pharma Letter","headline":"Neurocrine expands portfolio with buy of Soleno Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxQLXM3NFlNMVduazdCaXJOYWdyOTlYamZGM1JyZHBPZDhTaVFwdVhscnJxNmFSXzNkdlVCcV9XTTFoTW1KSkNFaF9kbWtFdlNULWRmSHhwdi1NdzhMS1dwUXVPZVlpc1BZOEdLeF8zaFVKWTZGc3ZYNDZkOFg1VURNWXNKaDk0c29vSTlySjc1cWpJME1jZEhhZV9CSEhQcm9iNy15UDhGVGNsdm1oUUVfQTJrT0ExVUp5WVA3UUxkUzg2QmFVYmh3YnNiUjJvMzJ0TDRPR21B?oc=5","date":"2026-04-07","type":"deal","source":"The Daily Upside","summary":"Neurocrine Scoops Up Hunger-Drug Maker in Latest Multi-Billion-Dollar Pharma Deal - The Daily Upside","headline":"Neurocrine Scoops Up Hunger-Drug Maker in Latest Multi-Billion-Dollar Pharma Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxPdWY0RWowRU1kRVBoQkg4anJxMXNBYUFqRDJyTEkyLXZYVkt6Nk82SVBrMmVmcTcwYlhGSE80bmZjWFJSVWFLYWhZdDhoWHk5WVpnNUdQNFpRQkxqcFhVV2p2cmNZZDVNMENCX0FBOXlDd3B0b2FfUjl5RlJvSklPWkY4OA?oc=5","date":"2026-04-06","type":"deal","source":"Barron's","summary":"Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. - Barron's","headline":"Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. - Barron'","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPNlowTW9qbmNjQWJzWjU4b04xMF9lcmtwNTEzdTFFdkMwWnh4N2J1NWZVa21Ca1J4b29EemYtMVJXaENUaUdQTk9TWE9ka2ZrRVdfWWtJN0drZTRqY1RIRG5PMmowNW9kTDRweXhVYk05T3cwUFFwX0xJNmZqdF81NzZZLWFLX2RacVlvYmVqR0h1T1JydFZCVlk3SEJRZFF4Vzl5QUExU0V5YzJ6bUhyVG5fX0cyNEdWMVVCZGpPUUQ2UQ?oc=5","date":"2026-04-06","type":"deal","source":"Fierce Pharma","summary":"Neurocrine, eying ‘blockbuster in the making,’ strikes its largest-ever M&A deal with $2.9B Soleno buyout - Fierce Pharma","headline":"Neurocrine, eying ‘blockbuster in the making,’ strikes its largest-ever M&A deal with $2.9B Soleno buyout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPNzdDNi1YNFVWdWxPUm1XWFlJdTFTdHY4Z0FSQWpyQ2kwUHZ1ZFdNc19XVUxsaDIxV3E1bDJlYVZaV1E5bElGdjl4TnBJeENHV0pvMjhIWGVPUC1ZazZQdW9RMUR6UWNob2hFRDFfMTR1QkdWVW5feERJRThzSk9uWUd6ZTBYVE1NWi1DMW1Wbl83cnFKOFFkaHFoMXhYdF9mZTNEWGVfaEJScW84bG96U3RHY3QxVG5o?oc=5","date":"2026-04-06","type":"deal","source":"Reuters","summary":"Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout - Reuters","headline":"Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNZFZwOUlJVVRFbHJCSFdGNnBGNF9kblp5YTdUM3ZJVjg0aGJyNi13MU9Xem5mM0FzbHpYYXgxM1NyTTVyRzVPZ1FTeVJfb1c2R3RjbzRQSmZ3MFk5SEpLd2xzbGxqS3RUWm9tVEFNc3V2Ujk3UE0yM1JrU3N2bDRwLTd3TkdPMl81UzljMGtMQVNIeUlKVGJMNGZB?oc=5","date":"2026-04-06","type":"deal","source":"Pharmaceutical Executive","summary":"Neurocrine Biosciences Agrees to Acquire Soleno Therapeutics | PharmExec - Pharmaceutical Executive","headline":"Neurocrine Biosciences Agrees to Acquire Soleno Therapeutics | PharmExec","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPOWwwNElpTGl0WjJSSk1iUGl0cDAzZm1KcjhleTE4Z2ZWaVhiVXpReDBVazRaQUdFOGtjWkNGcGRFX183SnJEMTJPNExwYVZxZjBGMTJBYktaVDJHRDdBbWVpWEgzMzAzZjM5MmZEM2FkZ2VoUV8yTWc3c2dzbGNZZG9lRVBmSXlDdzRYVjBkSlBSWnRmNFY0SndsNkNDNEk4WUNSM1d4UUdVYkNzQjRmSE1heEdEUQ?oc=5","date":"2026-04-06","type":"deal","source":"Contract Pharma","summary":"Neurocrine Biosciences Agrees to Acquire Soleno Therapeutics for $2.9B - Contract Pharma","headline":"Neurocrine Biosciences Agrees to Acquire Soleno Therapeutics for $2.9B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxPcjlMQTFnYXEzR1RLQUdWdE1EWW13OG1WUGx2cXNIZHZmbGxhU3ZILTlTNEwtdjAzckV6em1TZEc4MjBtM1l0RzRicUY2QWxTcnM2U3E2UXNtN094N3o5djh0R0h0Wll4aFZvSW54N0liMllBVGtldk42MHBDWldGQVUyZlZLWHY5QmZ6cTJILWhDVndJOWlUYWppWWlaeThIRHY5Y2l1dnRGTnRYQkJlVWZPVkxrd0o0UGZpaFROVWt6Q1Fs?oc=5","date":"2026-04-06","type":"deal","source":"MSN","summary":"This pharma stock is surging 40%. Neurocrine is buying it in $2.9 billion deal. - MSN","headline":"This pharma stock is surging 40%. Neurocrine is buying it in $2.9 billion deal.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOSTNKMHlNczVXNXpaTXVNRTV2M0RDS3FlTnhsZ0dkTGJUVzctSjBCY1dkWC1vMW5tOThrY3IydEV5Rk51T0lrdGp5NEVsQ0NtdEwtYTBpREFKUVh1T0d6ZW1zNmVTbnYxWUxIT3JnTVNkcEhiR3JXMVF3NXVyZ1RxU0pjbTFhU3BpVTJMWmNNTXBIZU5GV3ZnZFRxOG4?oc=5","date":"2026-04-06","type":"deal","source":"Pharmaceutical Executive","summary":"Neurocrine Enters $2.9 Billion Agreement to Acquire Soleno Therapeutics - Pharmaceutical Executive","headline":"Neurocrine Enters $2.9 Billion Agreement to Acquire Soleno Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOMGhMcXlCV2tSOXBhTWlPVF8wZE5FcldlZFp6Mm0tdzFtS0prVFltTHg3MDJWRC1tMmdxYXRhRGFOMXl0Z3hxcnhGN1VxLWx2MjU1dHlIeDNvcGpraFd3eW1LLXJ2SWl3aG84OFBjb0p4WnlPbXZ3Q3FRTmZDaFpuN08wM1dQRHJ2bExBTzllSDFFWTRXYWZROVNHTQ?oc=5","date":"2026-02-12","type":"earnings","source":"BioPharma Dive","summary":"Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor - BioPharma Dive","headline":"Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNdnZabTA4ZEpOeWNsRnowTU40bDkybl94Q29KekQ4c21aRFdfczV6Q0x4d0JJcHFYdUZkbVhmWGRnYVJUVUR0alJaYkNFb0J6UEV2bGk3RTFkN2ZDWk9MVmFjbnNWcU5hRGw5Rmx3aHp1eXJ1SVpKS2ZnTzdoOHVTem9zNmZiWEcyYVZKSW9SWldTS1VVUmtRcXlkS0FsQXBIc1QyZE96Z0dYLV9FTFRz?oc=5","date":"2025-11-11","type":"trial","source":"fiercebiotech.com","summary":"Neurocrine's depression drug is latest asset from Takeda pact to flunk a phase 2 trial - fiercebiotech.com","headline":"Neurocrine's depression drug is latest asset from Takeda pact to flunk a phase 2 trial","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":1,"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}